Logo image of SRTS

SENSUS HEALTHCARE INC (SRTS) Stock Fundamental Analysis

NASDAQ:SRTS - Nasdaq - US81728J1097 - Common Stock - Currency: USD

4.33  0 (0%)

Fundamental Rating

6

Overall SRTS gets a fundamental rating of 6 out of 10. We evaluated SRTS against 190 industry peers in the Health Care Equipment & Supplies industry. SRTS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. SRTS is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

SRTS had positive earnings in the past year.
In the past year SRTS has reported a negative cash flow from operations.
SRTS had positive earnings in 4 of the past 5 years.
SRTS had a negative operating cash flow in each of the past 5 years.
SRTS Yearly Net Income VS EBIT VS OCF VS FCFSRTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

SRTS has a Return On Assets of 10.69%. This is amongst the best in the industry. SRTS outperforms 92.59% of its industry peers.
SRTS has a Return On Equity of 11.91%. This is amongst the best in the industry. SRTS outperforms 87.30% of its industry peers.
The Return On Invested Capital of SRTS (10.64%) is better than 92.59% of its industry peers.
Industry RankSector Rank
ROA 10.69%
ROE 11.91%
ROIC 10.64%
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
SRTS Yearly ROA, ROE, ROICSRTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

With an excellent Profit Margin value of 15.90%, SRTS belongs to the best of the industry, outperforming 92.06% of the companies in the same industry.
SRTS's Profit Margin has been stable in the last couple of years.
SRTS's Operating Margin of 19.35% is amongst the best of the industry. SRTS outperforms 92.06% of its industry peers.
In the last couple of years the Operating Margin of SRTS has grown nicely.
SRTS has a Gross Margin (58.44%) which is in line with its industry peers.
In the last couple of years the Gross Margin of SRTS has declined.
Industry RankSector Rank
OM 19.35%
PM (TTM) 15.9%
GM 58.44%
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
SRTS Yearly Profit, Operating, Gross MarginsSRTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

9

2. Health

2.1 Basic Checks

SRTS has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, SRTS has more shares outstanding
The number of shares outstanding for SRTS remains at a similar level compared to 5 years ago.
There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRTS Yearly Shares OutstandingSRTS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
SRTS Yearly Total Debt VS Total AssetsSRTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

SRTS has an Altman-Z score of 9.15. This indicates that SRTS is financially healthy and has little risk of bankruptcy at the moment.
SRTS has a better Altman-Z score (9.15) than 90.48% of its industry peers.
There is no outstanding debt for SRTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 9.15
ROIC/WACC1.19
WACC8.97%
SRTS Yearly LT Debt VS Equity VS FCFSRTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

A Current Ratio of 9.64 indicates that SRTS has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.64, SRTS belongs to the top of the industry, outperforming 91.53% of the companies in the same industry.
A Quick Ratio of 7.36 indicates that SRTS has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.36, SRTS belongs to the best of the industry, outperforming 88.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.64
Quick Ratio 7.36
SRTS Yearly Current Assets VS Current LiabilitesSRTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

SRTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1233.33%, which is quite impressive.
SRTS shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.56% yearly.
Looking at the last year, SRTS shows a very strong growth in Revenue. The Revenue has grown by 71.29%.
Measured over the past years, SRTS shows a quite strong growth in Revenue. The Revenue has been growing by 8.93% on average per year.
EPS 1Y (TTM)1233.33%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-65.38%
Revenue 1Y (TTM)71.29%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%3.99%

3.2 Future

SRTS is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.81% yearly.
SRTS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.42% yearly.
EPS Next Y-16.87%
EPS Next 2Y24.21%
EPS Next 3Y13.28%
EPS Next 5Y-2.81%
Revenue Next Year5.53%
Revenue Next 2Y17.8%
Revenue Next 3Y16.63%
Revenue Next 5Y14.42%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SRTS Yearly Revenue VS EstimatesSRTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
SRTS Yearly EPS VS EstimatesSRTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

SRTS is valuated reasonably with a Price/Earnings ratio of 10.82.
Compared to the rest of the industry, the Price/Earnings ratio of SRTS indicates a rather cheap valuation: SRTS is cheaper than 94.18% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of SRTS to the average of the S&P500 Index (28.22), we can say SRTS is valued rather cheaply.
SRTS is valuated correctly with a Price/Forward Earnings ratio of 13.02.
86.24% of the companies in the same industry are more expensive than SRTS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 20.86. SRTS is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 10.83
Fwd PE 13.02
SRTS Price Earnings VS Forward Price EarningsSRTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, SRTS is valued cheaper than 97.35% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 5.8
SRTS Per share dataSRTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

SRTS has a very decent profitability rating, which may justify a higher PE ratio.
SRTS's earnings are expected to grow with 13.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.21%
EPS Next 3Y13.28%

More info and screens

0

5. Dividend

5.1 Amount

SRTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSUS HEALTHCARE INC

NASDAQ:SRTS (5/2/2025, 8:24:13 PM)

4.33

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-05 2025-02-05/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners30.36%
Inst Owner Change0.45%
Ins Owners16.52%
Ins Owner Change2.22%
Market Cap71.44M
Analysts81.82
Price Target12.24 (182.68%)
Short Float %6.45%
Short Ratio5.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)378.72%
Min EPS beat(2)-28.84%
Max EPS beat(2)786.28%
EPS beat(4)3
Avg EPS beat(4)356.8%
Min EPS beat(4)-28.84%
Max EPS beat(4)786.28%
EPS beat(8)5
Avg EPS beat(8)128.53%
EPS beat(12)6
Avg EPS beat(12)83.23%
EPS beat(16)10
Avg EPS beat(16)83.96%
Revenue beat(2)2
Avg Revenue beat(2)32.56%
Min Revenue beat(2)18.13%
Max Revenue beat(2)47%
Revenue beat(4)4
Avg Revenue beat(4)62.06%
Min Revenue beat(4)18.13%
Max Revenue beat(4)153.76%
Revenue beat(8)5
Avg Revenue beat(8)19.39%
Revenue beat(12)7
Avg Revenue beat(12)18.43%
Revenue beat(16)9
Avg Revenue beat(16)14.96%
PT rev (1m)-7.69%
PT rev (3m)4.35%
EPS NQ rev (1m)-29.17%
EPS NQ rev (3m)-71.67%
EPS NY rev (1m)-4.68%
EPS NY rev (3m)-49.06%
Revenue NQ rev (1m)-6.61%
Revenue NQ rev (3m)-31.82%
Revenue NY rev (1m)-6.56%
Revenue NY rev (3m)-15.26%
Valuation
Industry RankSector Rank
PE 10.83
Fwd PE 13.02
P/S 1.71
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB 1.28
EV/EBITDA 5.8
EPS(TTM)0.4
EY9.24%
EPS(NY)0.33
Fwd EY7.68%
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS2.53
BVpS3.38
TBVpS3.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 10.69%
ROE 11.91%
ROCE 14.37%
ROIC 10.64%
ROICexc 17.5%
ROICexgc 17.5%
OM 19.35%
PM (TTM) 15.9%
GM 58.44%
FCFM N/A
ROA(3y)18.11%
ROA(5y)8.54%
ROE(3y)21.11%
ROE(5y)9.47%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y-12.67%
ROICexcg growth 5YN/A
ROICexc growth 3Y-12.29%
ROICexc growth 5YN/A
OM growth 3Y8.29%
OM growth 5YN/A
PM growth 3Y1.43%
PM growth 5YN/A
GM growth 3Y-2.39%
GM growth 5Y-1.93%
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 63.89%
Cap/Sales 0.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.64
Quick Ratio 7.36
Altman-Z 9.15
F-Score5
WACC8.97%
ROIC/WACC1.19
Cap/Depr(3y)54.52%
Cap/Depr(5y)46.98%
Cap/Sales(3y)0.65%
Cap/Sales(5y)1.24%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1233.33%
EPS 3Y18.56%
EPS 5YN/A
EPS Q2Q%-65.38%
EPS Next Y-16.87%
EPS Next 2Y24.21%
EPS Next 3Y13.28%
EPS Next 5Y-2.81%
Revenue 1Y (TTM)71.29%
Revenue growth 3Y15.63%
Revenue growth 5Y8.93%
Sales Q2Q%3.99%
Revenue Next Year5.53%
Revenue Next 2Y17.8%
Revenue Next 3Y16.63%
Revenue Next 5Y14.42%
EBIT growth 1Y2158.52%
EBIT growth 3Y25.22%
EBIT growth 5YN/A
EBIT Next Year-12.87%
EBIT Next 3Y19.35%
EBIT Next 5Y37.13%
FCF growth 1Y53.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y61.26%
OCF growth 3YN/A
OCF growth 5YN/A